Precisis AG: Scientific launch of Precisis' CobraLeaf(R)
(firmenpresse) - (DGAP-Media / 18.12.2012 / 09:37)
Heidelberg - Precisis AG have now presented their newest development, the
CobraLeaf(R) multi leaf collimator for Radiotherapy, scientifically in the
emerging markets. With the expectations highly excelled, both Precisis AG
and Radiation oncologists express their excitement about the soon market
launch.
Supported by the first scientific presentation at the annual AMPICON
conference (Conference of the Association of Medical Physicists in India)
in Mangalore, India, Precisis AG has now widely approached the target
market in the emerging countries.
The CobraLeaf(R) concept, which connects modern treatments methods in
radiotherapy with high cost-efficiency and maximum reliability for use in
low- and middle income countries, was stirring expectations since its first
publication in September 2012.
Dr. Lokesh Viswanath M.D Professor Radiation Oncology at the Kidwai
Memorial Institute of Oncology in Bangalore, India explains that 'there is
a real and urgent need to demonstrate to the world, that a cost-effective
3D Conformal Radiotherapy (CRT), which is the basic minimum standard of
care in Radiation Therapy can be given on a Telecobalt Machine with a MLC.
A simple low cost accessory like this will benefit many patients throughout
the world, especially in many developing nations. Hence, we deeply
appreciate the effort by Precisis AG and DKFZ to bring this to the market.'
The CobraLeaf(R) collimator, developed in close cooperation with the German
Cancer Research Center (DKFZ) in Heidelberg and the support of Best
Theratronics, Canada, is a mechanical beam limiting device which now makes
it possible, for the first time, to precisely customize the beam to the
tumor shape in cobalt machines.
'The exclusively positive feedback from first-hand users boosts our
conviction that this product is definitely going to change the treatment
for cancer patients throughout the world. This team of scientists,
experienced engineers and designers has done a great job in the last few
months to make this happen', says Stefan Ueltzhöffer, head of Innovation
Management at Precisis AG.
During ongoing improvements and testing, several reference centers for
immediate and broad distribution of the new method are beeing selected and
will be equipped beginning of 2013.
Further detailed information will soon be given to the public on
www.cobraleaf.com.
About Precisis AG
Precisis AG perceives itself as an innovative solution provider for
stereotactic neurosurgery and radiation therapy. Alongside the enhancement
of precision software systems that are already established in the market
such as PraezisPlus(R) and Virtuos(R), the Heidelberg-based medical
technology provider also works to advance the use of cranial brachytherapy,
precision neurosurgery and special radiotherapy techniques. Its
international team of ten employees is led by company president Dr. Angela
Liedler, an experienced healthcare marketing and enterprise professional.
About CobraLeaf(R)
The CobraLeaf(R) collimator, developed in close cooperation with the German
Cancer Research Center (DKFZ) in Heidelberg, is a mechanical beam limiting
device which now makes it possible, for the first time, to precisely
customize the beam to the tumor shape in cobalt machines.
In contrast to Linear accelorators (LINAC), Cobalt machines do not rely on
stable power supply and do tolerate voltage fluctuations. With
CobRaLeaf(R), their beam can now becustomized to the shape of the tumor.
This improves the impact on the cancerous tissue while sparing the
surrounding healthy tissue. This high precision treatment technique in
radiotherapy was exclusive to wealthy healthcare infrastructures, but can
now be offered to a much wider range of patients.
About DKFZ
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
with its more than 2,500 employees is the largest biomedical research
institute in Germany. At DKFZ, more than 1,000 scientists investigate how
cancer develops, identify cancer risk factors and endeavor to find new
strategies to prevent people from getting cancer. They develop novel
approaches to make tumor diagnosis more precise and treatment of cancer
patients more successful. Jointly with Heidelberg University Hospital, DKFZ
has established the National Center for Tumor Diseases (NCT) Heidelberg
where promising approaches from cancer research are translated into the
clinic. The staff of the Cancer Information Service (KID) offers
information about the widespread disease of cancer for patients, their
families, and the general public. The center is a member of the Helmholtz
Association of National Research Centers. Ninety percent of its funding
comes from the German Federal Ministry of Education and Research and the
remaining ten percent from the State of Baden-Württemberg.
End of Media Release
The picture belonging to this press release can be found here:
http://newsfeed2.equitystory.com/precisis/197279.html
Caption: Erste wissenschaftliche Präsentation des Precisis
CobraLeaf(R)
---------------------------------------------------------------------
Issuer: Precisis AG
Key word(s): Research/Technology
18.12.2012 Dissemination of a Press Release, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
197279 18.12.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="EAGLE HILL AWARDS PRELIMINARY FEASIBILITY STUDY AS THE MAJOR STEP IN SATISFYING EARN-IN OBLIGATIONS AT WINDFALL LAKEDatum: 18.12.2012 - 09:37 Uhr
Sprache: Deutsch
News-ID 213624
Anzahl Zeichen: 6476
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 445 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Precisis AG: Scientific launch of Precisis' CobraLeaf(R)"
steht unter der journalistisch-redaktionellen Verantwortung von
Precisis AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
